[Skip to Content]
Breast Cancer

Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Breast Cancer Screening

JAMA Oncology
July 5, 2018 Audio Author Interview 12 min 11 sec
<title>Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Breast Cancer Screening</title>
Backward 15 Play Pause Forward 15
1x
0:00 / 0:00
Download MP3

Interview with Nora Pashayan, BSc MSc MSt MD PhD FFPH, author of Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model
Subscribe

Subscribe on your favorite podcast source to receive future episodes of this podcast.
Learn more about this JAMA Network podcast here

Related Articles

  1. Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Breast Cancer Screening

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

See More About

Breast Cancer Cancer Screening, Prevention, Control Oncology Cancer Epidemiology Women's Health
Close

Name Your Search

Save Search
Privacy Policy|Terms of Use
Close
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
Close
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue